CYDY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 21:34):

Stats
今日成交量	36 123.00
平均成交量	2.22M
市值	139.37M
EPS	$-0.0121 ( 2024-04-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.34
ATR14	$0.00200 (1.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Lalezari Jacob P	Buy	3 000 000	Non-qualified stock option (right to buy)
2024-02-01	Cohen Mitchell	Buy	0
2024-01-03	Migliarese Antonio	Buy	1 000 000	Non-qualified stock option (right to buy)
2024-01-03	Migliarese Antonio	Buy	630 222	Non-qualified stock option (right to buy)
2024-01-03	Migliarese Antonio	Buy	100 000	Non-qualified stock option (right to buy)

INSIDER POWER
73.49
Last 91 transactions
Buy: 23 178 436 \| Sell: 2 742 551

音量相关性

長: 0.15 (neutral)

短: 0.12 (neutral)

Signal:(35.741) Neutral

CytoDyn Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CytoDyn Inc. 相关性 - 货币/商品

0.20
( neutral )

0.44
( neutral )

0.00
( neutral )

0.66
( moderate )

CytoDyn Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-175 000 (0.00 %)
EPS:	$-0.0954

FY	2023
营收:	$0
毛利润:	$-175 000 (0.00 %)
EPS:	$-0.0954

FY	2022
营收:	$266 000
毛利润:	$213 000 (80.08 %)
EPS:	$-0.430

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.270

Financial Reports:

No articles found.

CytoDyn Inc.

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.